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Peter McKenna—Yes
After the discovery of chlorpromazine in 1952 and the
subsequent rise of biological psychiatry, the mainstream view
of schizophrenia became that it was amenable only to drug
treatment. But everything changed in 1997 when a pioneering
trial found that drug resistant patients improved when given a
form of cognitive therapy adapted to target delusions and
hallucinations, two of the core “positive” symptoms of
schizophrenia.1Many other trials—more than 50 to date—have
since followed.
Problems with the evidence
Promising results in early studies is one thing; demonstrating
that a treatment is effective in large, well controlled trials is
another. And it is here that cognitive behavioural therapy for
schizophrenia has run into difficulties. There have been around
nine moderately sized or large (35-257 participants in the
cognitive therapy group), blind trials comparing cognitive
behavioural therapy with usual treatment or a control
psychological intervention (trials of psychotherapy are invariably
carried out under single blind rather than double-blind
conditions). Only two of these nine methodologically rigorous
trials have had positive results on their primary outcomes of
overall symptoms, positive symptoms, or relapse at the end of
the treatment period,2 3 and in one of these the authors noted
that the blinding became compromised as the trial went on.3
Notwithstanding the mixed signals from these and many other
smaller or less rigorous studies, meta-analyses over the years
have generally been supportive. The leading example here is
unquestionably the meta-analysis, or rather series of
meta-analyses, carried out for the 2009 National Institute for
Health and Care Excellence’s schizophrenia guideline.4 On the
basis of these, NICE concluded that cognitive therapy was
effective in reducing rates of readmission to hospital and
duration of admission. It was also judged to be effective in
reducing overall symptom severity, both at the end of treatment
and after up to 12 months’ follow-up. Effectiveness against
positive symptoms was more limited, but evidence was
marshalled for benefits on hallucinations.
However, this meta-analysis was flawed. It examined a large
number of outcome measures in two main
comparisons—cognitive behavioural therapy versus standard
care and cognitive behavioural therapy versus other active
(psychological) treatments. These included not just readmission
rates and symptoms but also relapse, social and occupational
functioning, mortality, suicide, and insight; many of the
measures were non-independent—for example, symptoms at
six, 12, and 18 months’ follow-up, and summed positive
symptoms as well as separate ratings for delusions and
hallucinations, the latter with various subsidiary measures such
as command hallucinations, malevolence, and omniscience.
Slightly under half of the 110 individual meta-analyses
((excluding sensitivity analyses, re-analyses with outliers
removed, etc) carried out for these two main comparisons
contained only one or two studies. In these circumstances, there
is a risk that some of the positive findings will have been down
to chance. In fact, correcting for multiple comparisons using
false discovery rate, a method appropriate for correlated
variables,5 we found that the individual meta-analyses for only
six out of 65 measures remained significant in the comparison
of cognitive therapy with standard care, mainly related to aspects
of hallucinations, and none of the 45 in the comparison with
other active treatments (data available from the authors on
request).
Negative results
Subsequent meta-analyses have had more sobering findings. In
2012, the Cochrane Collaboration compared cognitive therapy
with other psychological therapies, both active and inactive,
and concluded that there was no clear and convincing evidence
of benefits for relapse, readmission to hospital, or a range of
mental state measures.6Another similar meta-analysis found an
effect size for symptom scores of just 0.16 compared with other
psychological interventions.7
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We recently comprehensively reviewed all randomised trials
carried out worldwide to date.8 The crude pooled effect size was
0.33 for overall symptoms in 34 studies and 0.25 for positive
symptoms in 33 studies, both values being in the small range.
We also examined the influence of sources of bias, something
that previous meta-analyses had done to only a limited extent.
Use of blind evaluations was found to exert a highly significant
effect, with the effect size falling to 0.15 in 20 blind studies of
overall symptoms and to 0.08 in 20 blind studies of positive
symptoms; the last result was non-significant. We found no
compelling evidence for an effect on hallucinations.
For the time being, the cognitive therapy for schizophrenia ship
sails on. The treatment is officially mandated by the English
government for all patients with schizophrenia, and its
implementation is being monitored. Large grants to explore
ever wider applications in psychotic patients continue to be
applied for and awarded. A recent News Focus article in Science
was scrupulously balanced but nevertheless came down firmly
in favour of cognitive behavioural therapy and other
psychological treatments being effective in schizophrenia.9 But
behind all the fanfare, it has been evident for some time that
this form of treatment is being kept afloat only by efforts to play
up weak or equivocal findings and to discredit the increasingly
ominous results from meta-analysis.
David Kingdon—No
If psychosis is biological in origin, how can a psychological
therapy be expected to have any effect on it? Psychological
therapies in psychosis have done harm in the past, with families
being falsely accused of causing psychosis. It is entirely
reasonable therefore to question whether the development of
psychological interventions could be harmful or ineffective and
so displace valuable resources from areas of need.10
But non-biological approaches—for example, occupational
therapy, physiotherapy, and psychological approaches—are
accepted as having a place in unequivocally biological
conditions such as stroke. Is there anything intrinsically wrong
with them having a place in management of psychosis? A
substantial body of work now shows the relevance of
psychological11 and social influences.12
Evidence shows benefit
Meta-analyses of cognitive therapy for psychosis have
consistently shown an effect size of around 0.3.7 But not
everyone agrees that this translates into clinical effectiveness.
McKenna and colleagues have consistently concluded that,
despite recently finding a similar effect size to other
meta-analyses, no publication bias, and no significant effect of
non-specific therapy controls on differential outcome, cognitive
behavioural therapy for psychosis has been “oversold.”8 They
suggest that there have been few successful studies and that
meta-analysis has been necessary to demonstrate any effect.
This is an extraordinary interpretation of their own forest plots,
which show that in nearly all the studies selected cognitive
behavioural therapy is favoured over controls. They list many
studies that have achieved significant results for their primary
outcome measures. Among the studies that they describe as
failures, they include a comparison of cognitive behavioural
therapy with befriending published by Archives of General
Psychiatry that shows clinically significant effects at the end of
the trial period13 and a continuing significant effect at five
years.14
They remove studies from their final analysis that they describe
as methodologically unsound. This is not because of flaws in
randomisation procedure or incompleteness of outcome data,
but because they are deemed to be unmasked—that is, treatment
allocation was not confirmed as concealed from assessors. On
this basis, they removed 10 studies from the 30 analysed (already
reduced from over 50), thereby reducing the overall effect size
to 0.15, but in several instances, such removal is disputable.
Many of the studies described as “unclear” indicate that
independence or masking from allocation occurred and in others
the authors have confirmed that it occurred.
There are, of course, difficulties with meta-analyses. Studies
use different methods, types of therapy, inclusion and exclusion
criteria, and outcome measures, making comparison and
meta-analysis difficult. Direct replications in research into
cognitive behavioural therapy for psychosis are rare as public
funding bodies are continually seeking innovation (and for
studies to be methodologically sound). Rather than examining
the same techniques and populations, studies have used brief
interventions, examined therapy modifications, or been targeted
at specific patient groups. Some have therefore not shown
benefit for cognitive behavioural therapy because of the choice
of participants—for example, coexistence of substance
misuse15—or because of treatment problems, such as too brief
treatment periods.16 These studies continue to be included in
meta-analyses despite the fact that the treatment is not effective
when delivered in this way. This makes it all the more significant
that positive effect sizes exist.
Pharmaceutical standards
Would we be having this argument if cognitive behavioural
therapy was a drug? If an effect size of about 0.3 is accepted,
this is similar to that of clozapine compared with conventional
antipsychotics. 17 Clozapine is universally accepted as an
important additional treatment in psychosis but it does cause
substantial side effects. Cognitive behavioural therapy has fewer
side effects and those that do exist would generally be
considered less harmful. Clinical guidelines internationally
recommend the use of both clozapine and cognitive behavioural
therapy, but non-drug treatment has regrettably not benefited
from the communications and advertising budgets that
commercial support brings. If comparison is made with
promotion of the second generation antipsychotics, whose effect
size compared to the first generation is modest, then the idea
that cognitive behavioural therapy has been oversold becomes
even more difficult to sustain.
So who could be accused of overselling cognitive behavioural
therapy? International clinical guideline committees seem the
chief culprits, including the National Institute for Health and
Care Excellence (three committees have supported its use), the
Schizophrenia Patient Outcomes Research Team (two
committees), and national psychiatric associations in America,
Australasia, Germany, and many other countries.18 In the UK,
it is supported by the Schizophrenia Commission, the Royal
College of Psychiatrists, mental health charities, carers and,
finally, those who use services themselves. Can they all have
got it so wrong?
Cognitive behavioural therapy complements the use of
medication and family work within the context of mental health
services. It even seems to be acceptable to many people who
refuse to take medication, with early evidence suggesting that
it may reduce symptoms.19 Treatment is evolving as a thriving
research community investigates new approaches—for example,
mindfulness, focusing on worry, acceptance and commitment
therapy, and competitive memory training—and use in distinct
populations, such as those who have persistent symptoms despite
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taking clozapine.20 Psychosis remains a challenge: psychological
approaches do not hold all the answers, but the evidence
suggests that they can have an important and acceptable role in
helping people cope with very distressing and disabling
experiences.
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